Results 11 to 20 of about 3,363,784 (294)

Bladder cancer [PDF]

open access: yesNature Reviews Disease Primers, 2017
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after ...
Yair Lotan, Oner Sanli, Jakub Dobruch
exaly   +3 more sources

Bladder cancer

open access: yesNature Reviews Disease Primers, 2023
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease.
Lars Dyrskjøt   +2 more
exaly   +4 more sources

Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer

open access: yesBladder Cancer
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)’ led by the Bladder Cancer Task Force ...
Andrea Apolo   +31 more
doaj   +2 more sources

Bladder cancer [PDF]

open access: yesThe Lancet, 2009
Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial tumours, which tend to recur but are generally not life threatening, and 30% presenting as muscle-invasive disease associated with a high risk of death from distant metastases.
Donald S, Kaufman   +2 more
  +9 more sources

Bladder cancer [PDF]

open access: yesPostgraduate Medical Journal, 1996
SummaryBladder cancer is the fourth most common cancer in England and Wales. The most common presenting symptom is macroscopic haematuria. The management options for superficial and invasive bladder cancer depend on the stage at presentation. Most superficial bladder cancers are managed by transurethral resection and cytoscopic follow-up. The prognosis
H Y, Leung, T R, Griffiths, D E, Neal
openaire   +4 more sources

Bladder Cancer [PDF]

open access: yesThe Scientific World JOURNAL, 2011
To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan   +2 more
openaire   +5 more sources

Microarray analysis of pathways involved in bladder cancer invasion and metastasis. [PDF]

open access: yes, 2008
MDHypoxia-inducible genes have been linked to the aggressive phenotype of cancer. However, nearly all work on hypoxia-regulated genes has been conducted in vitro on cell lines.
Ord, Jonathan J
core   +4 more sources

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning

open access: yesFrontiers in Surgery, 2022
IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward   +4 more
doaj   +1 more source

Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes

open access: yesGenome Medicine, 2022
Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel   +16 more
doaj   +1 more source

STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes

open access: yesEuropean Urology Open Science, 2022
Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy